Discontinued — last reported Q3 '21

Other

Reclassification from AOCI, Net of Tax

Vertex Pharmaceuticals Reclassification from AOCI, Net of Tax remained flat by 0.0% to -$12.40M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 291.5%, from $6.48M to -$12.40M. Over 2 years (FY 2023 to FY 2025), Reclassification from AOCI, Net of Tax shows a downward trend with a 44.7% CAGR.

Analysis

StatementIncome Statement
SectionOther
CategoryOther
SignalContext dependent
VolatilityModerate
First reportedQ1 2016
Last reportedQ3 2021

How to read this metric

High reclassifications often signal the realization of gains or losses from the sale of long-term assets or hedging instruments.

Detailed definition

Represents the amount of gains or losses previously recorded in accumulated other comprehensive income that are now bein...

Peer comparison

Standard accounting adjustment for companies with complex hedging or investment portfolios.

Metric ID: is_tmo_reclassification_from_aoci_net_of_tax

Historical Data

3 years
 FY'23FY'24FY'25
Value$23.70M$25.90M-$49.60M
YoY Change—+9.3%-291.5%
Range-$49.60M – $25.90M
CAGR+44.7%
Avg YoY Growth-141.1%
Median YoY Growth-141.1%

Frequently Asked Questions

What is Vertex Pharmaceuticals's reclassification from aoci, net of tax?
Vertex Pharmaceuticals (VRTX) reported reclassification from aoci, net of tax of -$12.40M in Q4 2025.
How has Vertex Pharmaceuticals's reclassification from aoci, net of tax changed year-over-year?
Vertex Pharmaceuticals's reclassification from aoci, net of tax decreased by 291.5% year-over-year, from $6.48M to -$12.40M.
What is the long-term trend for Vertex Pharmaceuticals's reclassification from aoci, net of tax?
Over 2 years (2023 to 2025), Vertex Pharmaceuticals's reclassification from aoci, net of tax has grown at a 44.7% compound annual growth rate (CAGR), from $23.70M to -$49.60M.
What does reclassification from aoci, net of tax mean?
The portion of past comprehensive income gains or losses now recognized in current earnings.

Cookie Preferences

We use cookies for analytics. See our Privacy and Cookie Policy.